leisure time -WSS

leisure time

author：fashion 2025-09-30 16:24:23 - browse：1728

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Dairy farmers resist CDC push for PPE against bird flu virus

WSS

After gene therapy, two congenitally deaf children hear for the first time

5 important ways Henrietta Lacks changed medical science

H5N1 bird flu: what we're starting to learn about infection in cows

Brain worms: The science behind RFK Jr.'s parasitic infection

What the airline industry can learn from medicine

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

focus

leisure time

entertainment

Medical records are filled with copy

Micronoma's microbiome cancer diagnostic approach under fire

Supreme Court strikes down use of affirmative action

Study: Adult vaccinations pay for themselves in societal benefits

Continuity nursing helped my family in our darkest PICU moments

‘Oppenheimer’ and the risks of AI in health care

Medicare details structure of new drug price negotiation program

Researchers on aging grapple with how to calculate biological age

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Telehealth startups turn to complex chronic diseases

focus

After gene therapy, two congenitally deaf children hear for the first time

Researchers on aging grapple with how to calculate biological age

NIH launches clinical trials and new research office for long Covid

Micronoma's microbiome cancer diagnostic approach under fire

Readout LOUD podcast: What to know about H5N1 bird flu

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

knowledge

leisure time

entertainment

knowledge